Metabolic and vascular effects of silybin in hypertensive patients with high 1-h post-load plasma glucose.
Adult
Blood Glucose
/ metabolism
Drug Combinations
Female
Glucose Tolerance Test
Humans
Hypertension
/ drug therapy
Insulin Resistance
Longitudinal Studies
Male
Middle Aged
Phospholipids
/ therapeutic use
Pilot Projects
Protective Agents
/ therapeutic use
Silybin
/ therapeutic use
Treatment Outcome
Vitamin E
/ therapeutic use
Essential hypertension
Insulin resistance
Silybin
Vascular damage
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
04
08
2018
accepted:
13
09
2018
pubmed:
21
9
2018
medline:
20
8
2019
entrez:
21
9
2018
Statut:
ppublish
Résumé
Hypertensive patients with normal glucose tolerance (NGT) but 1-h post-load plasma glucose ≥ 155 mg/dl (1-h high), during an oral glucose tolerance test (OGTT), show higher insulin resistance and multiple target organ damages. Experimental and clinical studies demonstrate that silybin presents anti-inflammatory and metabolic effects, improving insulin resistance and endothelial dysfunction. This study aims to evaluate the effects of the complex silybin-vitamin E and phospholipids on inflammatory, metabolic and vascular parameters in NGT 1-h high hypertensive patients. This is a pilot, single arm, interventional, longitudinal study enrolling 50 Caucasian NGT 1-h high hypertensive outpatients, 27 men and 23 women, age range 42-60 years (mean + SD = 52 ± 7). After 6 months of silybin intake, there is a significant improvement in metabolic profile. The glucose response during OGTT significantly improves (AUCglucose
Identifiants
pubmed: 30232738
doi: 10.1007/s11739-018-1951-6
pii: 10.1007/s11739-018-1951-6
doi:
Substances chimiques
Blood Glucose
0
Drug Combinations
0
Phospholipids
0
Protective Agents
0
Vitamin E
1406-18-4
Silybin
4RKY41TBTF
Types de publication
Journal Article
Langues
eng
Pagination
77-84Commentaires et corrections
Type : CommentIn
Références
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
J Am Coll Cardiol. 2003 May 21;41(10):1753-8
pubmed: 12767660
Am J Cardiol. 2003 Nov 15;92(10):1234-7
pubmed: 14609609
Eur Heart J. 2005 May;26(9):921-7
pubmed: 15689344
J Am Coll Cardiol. 2005 Aug 2;46(3):518-23
pubmed: 16053968
Gut. 2006 Jun;55(6):901-2
pubmed: 16698763
Diabetes Care. 2007 Jan;30(1):89-94
pubmed: 17192339
Endocr Rev. 2007 Aug;28(5):463-91
pubmed: 17525361
Diabetes Care. 2008 Aug;31(8):1550-5
pubmed: 18509205
J Hepatol. 2009 Jun;50(6):1102-11
pubmed: 19398228
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Hypertension. 2009 Aug;54(2):375-83
pubmed: 19564542
Diabetes Care. 2011 Jun;34(6):1406-11
pubmed: 21515837
World J Gastroenterol. 2011 May 14;17(18):2288-301
pubmed: 21633595
Braz J Med Biol Res. 2011 Jul;44(7):652-9
pubmed: 21755261
Cardiovasc Diabetol. 2011 Jul 14;10:62
pubmed: 21756303
Diabetes Care. 2011 Oct;34(10):2291-6
pubmed: 21911775
Int J Cardiol. 2013 May 10;165(2):322-6
pubmed: 21925746
Diabetes Care. 2012 Jan;35(1):153-7
pubmed: 22011411
Free Radic Biol Med. 2012 May 1;52(9):1658-65
pubmed: 22343419
Lancet. 2012 Aug 11;380(9841):601-10
pubmed: 22883509
PLoS One. 2012;7(9):e44470
pubmed: 23028545
Diabetes Care. 1990 Feb;13(2):172-5
pubmed: 2351014
Aging Clin Exp Res. 2013 Apr;25(1):9-15
pubmed: 23740628
Eur Heart J. 2013 Jul;34(28):2159-219
pubmed: 23771844
Int Immunopharmacol. 2013 Nov;17(3):714-20
pubmed: 24036369
Braz J Med Biol Res. 2015 May;48(5):440-6
pubmed: 25760026
J Clin Endocrinol Metab. 2015 Oct;100(10):3744-51
pubmed: 26274345
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Hypertension. 1996 Feb;27(2):168-75
pubmed: 8567037